Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

CCNE1

3 articles · Resources: NCBI Gene, OncoKB

Clinical · Bioinfo & AI

Computational screening of oncogenic genetic variations in tumor suppressor proteins driving gastric cancer pathogenesis

Mim FF, Sumiya TA, Khanam R, et al.

PloS one

This study employed a deep learning-based graph neural network model to identify genes and pathogenic genetic variations driving gastric cancer pathogenesis. Researchers focused on tumor suppressor proteins exhibiting both dysregulated expression and high mutation propensity. The model identified 1,886 relevant genes, with TP53, ERBB2, CDH1, and APC emerging as prominent hub genes. Missense and nonsense variants in TP53, CDH1, and APC were validated, affecting post-translational modification sites and correlating with altered patient survival. The study also highlighted EZH2 and miR-129-5p as key regulators and the dysregulation of oncogenes like CCNE1/2 and FGFR2.

Clinical · Molecular biology

Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology

Yap TA, Simpkins F, Porte M, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Synthetic lethality describes a genetic interaction where two specific genetic alterations together impair cell viability, while either alteration alone is compatible with survival. This concept offers promising therapeutic avenues for targeting previously undruggable cancer pathways. High-throughput screening technologies have facilitated the discovery of novel druggable synthetic lethal vulnerabilities, particularly in DNA damage response and epigenetic alterations. Clinically approved PARP inhibitors have validated this approach in BRCA-mutant cancers. Emerging strategies targeting PRMT5, MAT2A, WRN, PKMYT1, and WEE1 are currently undergoing late preclinical or early clinical evaluation.

Molecular biology · Bioinfo & AI

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer

Oda K, Shintani D, Nishijima A, et al.

Cancer science

This study aimed to develop a mutational signature-based biomarker (MSBM) to define homologous recombination deficiency (HRD) in advanced ovarian cancer, overcoming limitations of genomic scar-based assays. The MSBM integrates tumor-BRCA mutation status, Mutational Signature 3 similarity score, and the absence of CCNE1 amplification, derived from whole-exome sequencing. A phase II trial (MSBM-OL) validated this biomarker and evaluated the efficacy of olaparib maintenance monotherapy in HRD-positive patients. The study demonstrated that olaparib significantly extended progression-free survival (22.3 months) compared to a predefined 9-month threshold, confirming its clinical benefit as first-line maintenance therapy.